Literature DB >> 9363846

Direct reaction of oximes with sarin, soman, or tabun in vitro.

G Becker1, A Kawan, L Szinicz.   

Abstract

The direct reaction of seven pyridinium oximes with the nerve agents sarin, soman, and tabun was followed by a spectrophotometric method. The half-lives (t1/2) of the oximes, the first- and second-order rate constants (k1, k2), and the maximal reaction velocity (vmax) were calculated according to changes in the absorbance of the zwitterion (betaine) peak. In all cases the reaction velocity of the nerve agents with any of the oximes was highest with tabun, followed by sarin and then soman. Comparing the reaction rates of three therapeutically used oximes with the same nerve agent, the highest rate was obtained for soman with obidoxime, for sarin with 2-PAM, and for tabun with HI 6. The maximal reaction velocities reveal that the detoxification of the nerve agents by direct reaction with oximes and the subsequent decomposition of the phosphonyl oxime in vivo do not substantially contribute to the therapeutic effect of these antidotes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9363846     DOI: 10.1007/s002040050450

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  3 in total

1.  Non-quaternary oximes detoxify nerve agents and reactivate nerve agent-inhibited human butyrylcholinesterase.

Authors:  Gabriel Amitai; Alexander Plotnikov; Shira Chapman; Shlomi Lazar; Rellie Gez; Dan Loewenthal; Khriesto A Shurrush; Galit Cohen; Leonardo J Solmesky; Haim Barr; Alan J Russell
Journal:  Commun Biol       Date:  2021-05-14

2.  Reactivation of model cholinesterases by oximes and intermediate phosphyloximes: a computational study.

Authors:  Shubham Vyas; Christopher M Hadad
Journal:  Chem Biol Interact       Date:  2008-05-15       Impact factor: 5.192

Review 3.  Unequal efficacy of pyridinium oximes in acute organophosphate poisoning.

Authors:  Biljana Antonijevic; Milos P Stojiljkovic
Journal:  Clin Med Res       Date:  2007-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.